Cargando…
Glucose tolerance in fibromyalgia
OBJECTIVES: Fibromyalgia (FM) patients have an increased risk for glucose metabolism disturbances, and impaired glucose tolerance may be associated with symptom severity. Elevated levels of plasma lactate have been detected in FM patients. Both pyruvate and lactate are produced in glucose metabolism...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601335/ https://www.ncbi.nlm.nih.gov/pubmed/34797307 http://dx.doi.org/10.1097/MD.0000000000027803 |
_version_ | 1784601323666145280 |
---|---|
author | Zetterman, Teemu Markkula, Ritva Kalso, Eija |
author_facet | Zetterman, Teemu Markkula, Ritva Kalso, Eija |
author_sort | Zetterman, Teemu |
collection | PubMed |
description | OBJECTIVES: Fibromyalgia (FM) patients have an increased risk for glucose metabolism disturbances, and impaired glucose tolerance may be associated with symptom severity. Elevated levels of plasma lactate have been detected in FM patients. Both pyruvate and lactate are produced in glucose metabolism and reflect oxidative metabolism. The objective of our study was to analyse disturbances in glucose, pyruvate, or lactate metabolism in FM patients. METHODS: We measured plasma levels of glucose, pyruvate, and lactate during an oral glucose tolerance test in 40 non-diabetic, female FM patients and 30 age- and gender-matched healthy controls. RESULTS: FM patients showed a higher glycaemic response to the glucose load at 1 hour (F [1,68] = 10.4, P = .006) and 2 hours (F [1,68] = 7.80, P = .02), and higher glucose area under the curve (13.8 [SD 2.92] vs 11.6 [SD 2.31], P < .01), than healthy controls. Group differences were explained by higher body mass index and percentage of smokers among the FM patients. Pyruvate and lactate levels were similar in both groups. DISCUSSION: Impaired glucose regulation in FM patients is likely not due to FM itself, but to associated lifestyle factors. Our results highlight the importance of assessing the glucose regulation status and the lifestyle factors affecting glucose regulation in FM patients for prevention or early treatment of diabetes and associated complications. TRIAL REGISTRATION: ClinicalTrials.gov (NCT03300635) |
format | Online Article Text |
id | pubmed-8601335 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-86013352021-11-20 Glucose tolerance in fibromyalgia Zetterman, Teemu Markkula, Ritva Kalso, Eija Medicine (Baltimore) 6900 OBJECTIVES: Fibromyalgia (FM) patients have an increased risk for glucose metabolism disturbances, and impaired glucose tolerance may be associated with symptom severity. Elevated levels of plasma lactate have been detected in FM patients. Both pyruvate and lactate are produced in glucose metabolism and reflect oxidative metabolism. The objective of our study was to analyse disturbances in glucose, pyruvate, or lactate metabolism in FM patients. METHODS: We measured plasma levels of glucose, pyruvate, and lactate during an oral glucose tolerance test in 40 non-diabetic, female FM patients and 30 age- and gender-matched healthy controls. RESULTS: FM patients showed a higher glycaemic response to the glucose load at 1 hour (F [1,68] = 10.4, P = .006) and 2 hours (F [1,68] = 7.80, P = .02), and higher glucose area under the curve (13.8 [SD 2.92] vs 11.6 [SD 2.31], P < .01), than healthy controls. Group differences were explained by higher body mass index and percentage of smokers among the FM patients. Pyruvate and lactate levels were similar in both groups. DISCUSSION: Impaired glucose regulation in FM patients is likely not due to FM itself, but to associated lifestyle factors. Our results highlight the importance of assessing the glucose regulation status and the lifestyle factors affecting glucose regulation in FM patients for prevention or early treatment of diabetes and associated complications. TRIAL REGISTRATION: ClinicalTrials.gov (NCT03300635) Lippincott Williams & Wilkins 2021-11-19 /pmc/articles/PMC8601335/ /pubmed/34797307 http://dx.doi.org/10.1097/MD.0000000000027803 Text en Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) |
spellingShingle | 6900 Zetterman, Teemu Markkula, Ritva Kalso, Eija Glucose tolerance in fibromyalgia |
title | Glucose tolerance in fibromyalgia |
title_full | Glucose tolerance in fibromyalgia |
title_fullStr | Glucose tolerance in fibromyalgia |
title_full_unstemmed | Glucose tolerance in fibromyalgia |
title_short | Glucose tolerance in fibromyalgia |
title_sort | glucose tolerance in fibromyalgia |
topic | 6900 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601335/ https://www.ncbi.nlm.nih.gov/pubmed/34797307 http://dx.doi.org/10.1097/MD.0000000000027803 |
work_keys_str_mv | AT zettermanteemu glucosetoleranceinfibromyalgia AT markkularitva glucosetoleranceinfibromyalgia AT kalsoeija glucosetoleranceinfibromyalgia |